Last reviewed · How we verify
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells exert therapeutic effects through immunomodulation, anti-inflammatory signaling, and tissue repair via paracrine secretion of bioactive factors and direct cell-to-cell interactions.
Mesenchymal stem cells exert therapeutic effects through immunomodulation, anti-inflammatory signaling, and tissue repair by secreting bioactive factors and differentiating into specialized cell types. Used for Graft-versus-host disease (GVHD), Osteoarthritis, Myocardial infarction.
At a glance
| Generic name | Mesenchymal Stem Cells (MSCs) |
|---|---|
| Also known as | Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (MSCs), Allogeneic Bone Marrow Derived Mesenchymal Stem Cells, MSV (GMP-compliant MSCs manufactured by IBGM in Valladolid) |
| Sponsor | The Cleveland Clinic |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine, Immunology, Orthopedics |
| Phase | FDA-approved |
Mechanism of action
MSCs are multipotent stromal cells that suppress pro-inflammatory immune responses, promote tissue regeneration, and secrete cytokines and growth factors that reduce inflammation and support healing. They can differentiate into multiple cell types (osteocytes, chondrocytes, adipocytes) and modulate both innate and adaptive immunity through interaction with T cells, B cells, and macrophages. The therapeutic benefit derives from both their regenerative capacity and their ability to create an immunologically permissive microenvironment.
Approved indications
- Graft-versus-host disease (GVHD)
- Osteoarthritis
- Myocardial infarction
- Spinal cord injury
Common side effects
- Infusion-related reactions
- Infection
- Fever
- Hypersensitivity reactions
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- cfMSC Therapy for Diabetes (PHASE1, PHASE2)
- cfMSC Stem Cell Therapy Targeting COPD (PHASE1, PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis (PHASE1, PHASE2)
- PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesenchymal Stem Cells (MSCs) CI brief — competitive landscape report
- Mesenchymal Stem Cells (MSCs) updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI